by partially lowering somatostatin tone, this compound amplifies the response to any concurrent GHRH signal which is the mechanistic basis for the synergistic effect when combined with CJC-1295
A phase II human trial was initiated for ulcerative colitis, with encouraging preliminary results
Many patients start with Sermorelin to establish response, then switch to the CJC + Ipamorelin stack for stronger effect
The Signal Transduction lab is supported by the following: the Italian Association for Cancer Research (AIRC), Telethon, the Italian Ministry of Education, University and Research (PRIN/COFIN), and local funds from the University of Ferrara to P.P
Ricci G, De Maria F, Antonini G, Turella P, Bullo A, Stella L et al